1. Injectable composition in the form of a combined preparation for simultaneous, separate or sequential use to reduce, reduce or avoid the occurrence of skin reactions initiated by injection, in particular redness, ecchymosis, hematoma, bleeding, erythema, edema, necrosis, ulceration, swelling and / or inflammation containing hyaluronic acid (HA) or a pharmaceutically acceptable salt or derivative thereof as an excipient capable of filling skin tissues； α-adrenergic receptor agonist and lidocaine as an anesthetic. 2. The composition of claim 1, wherein the α-adrenergic receptor agonist is an α2-adrenergic receptor agonist. The composition of claim 1, wherein the α-adrenergic receptor agonist is brimonidine or xylometazoline or oxymetazoline. The composition of claim 1, wherein the composition comprises hyaluronic acid in an amount of from 1 to 2.5% by weight of the composition； adrenergic receptor agonist, preferably brimonidine in an amount of from 0.0001 to 1% by weight of the composition； lidocaine in an amount of from 0.01 to 3% by weight of the composition. 5. The composition according to claim 1 in the form of a combined preparation for simultaneous, separate or sequential use. The composition according to claim 1 in the form of a combined preparation for simultaneous, separate or sequential use for the prevention or treatment of skin defects, in particular wrinkles, wrinkles, skin impressions and scars. The composition of claim 1 for use in the prophylaxis or treatment of skin defects, in particular wrinkles, wrinkles, skin depressions and scars. The composition of claim 7 for use in order to reduce, reduce, or avoid occurrence1. Инъецируемая композиция в виде комбинированного препарата для одновременного, раздельного или последовательного применения для сокращения, уменьшения или избегания возникновения кожных реакций, инициируемых инъекцией, в частности красноты, экхимоза, гематомы, кровотечения, эритемы, отека, некроза, изъязвления, припухлости и/или восп
